e-learning
resources
Barcelona 2013
Tuesday, 10.09.2013
Factors associated with outcomes in COPD
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Neutrophil gelatinase-associated lipocalin (NGAL) is associated with a reduced decline in FVC in male COPD patients
G. R. HusebØ, M. Aanerud, T. Ueland, J. A. Hardie, P. S. Bakke, T. M. Eagan (Bergen, Oslo, Norway)
Source:
Annual Congress 2013 –Factors associated with outcomes in COPD
Session:
Factors associated with outcomes in COPD
Session type:
Thematic Poster Session
Number:
4222
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
G. R. HusebØ, M. Aanerud, T. Ueland, J. A. Hardie, P. S. Bakke, T. M. Eagan (Bergen, Oslo, Norway). Neutrophil gelatinase-associated lipocalin (NGAL) is associated with a reduced decline in FVC in male COPD patients. Eur Respir J 2013; 42: Suppl. 57, 4222
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Evidence-based eHealth for COPD
Related content which might interest you:
Increased neutrophil gelatinase-associated lipocalin (NGAL) promotes airway remodeling in chronic obstructive pulmonary disease (COPD)
Source: International Congress 2016 – Laboratory tests and cell biology in allergy and immunology
Year: 2016
LSC - 2019 - Neutrophil gelatinase-associated lipocalin and IL-6 – markers predictors for exacerbations in Asthma- COPD overlap, compared to COPD and Asthma
Source: International Congress 2019 – Clinical approach to asthma management
Year: 2019
Human neutrophil gelatinase-associated lipocalin: A new biomarker in asthma-COPD overlap syndrome
Source: International Congress 2016 – Notable abstracts on clinical problems related to asthma
Year: 2016
Neutrophil gelatinase-associated lipocalin in idiopathic pulmonary fibrosis
Source: Eur Respir J 2014; 43: 1807-1809
Year: 2014
Usefulness of the measurement of plasma neutrophil gelatinase-associated lipocalin as a biomarker for predicting prognosis in hospitalized patients with pneumonia
Source: International Congress 2018 – Predicting the future: biomarkers of respiratory infection
Year: 2018
Increased levels of human myeloperxidase (MPO) and neutrophil lipocalin (HNL/NGAL) in childhood asthma
Source: International Congress 2019 – Understanding, monitoring and targeting severe asthma
Year: 2019
Endothelial microparticles in sputum of COPD patients: A potential biomarker of disease
Source: International Congress 2015 – Systemic and airway biomarkers
Year: 2015
Neutrophil activity assessed using a novel serological marker of human neutrophil elastase degraded calprotectin is elevated in patients with COPD or IPF
Source: Virtual Congress 2021 – Advanced in vitro models for drug discovery
Year: 2021
Neutrophil elastase and IL-8 assessment in patients with COPD and asthma
Source: Eur Respir J 2005; 26: Suppl. 49, 61s
Year: 2005
Matrix metalloproteinase, hyaluronic acid and C-reactive protein: Are they really markers of lung obstruction at COPD but not cardiovascular comorbidity?
Source: International Congress 2015 – Notable abstracts in exacerbations, mechanisms and biomarkers in COPD
Year: 2015
Elevated serum IL-8: a biomarker indicating exacerbation-prone COPD
Source: International Congress 2017 – COPD biomarkers
Year: 2017
Inflammatory markers (IL-6, suPAR) and arterial stiffness parameters in COPD patients
Source: International Congress 2016 – Biomarkers and phenotypes of COPD
Year: 2016
Pro-surfactant protein B, a promising BAL biomarker of COPD progression in heavy smokers, is increased by budesonide/formoterol short-term therapy
Source: Annual Congress 2013 –Biomarkers in asthma and COPD
Year: 2013
Blood eosinophils relate more closely to reduced lung function than serum ECP or plasma EDN in young asthmatics
Source: International Congress 2016 – Systemic biomarkers
Year: 2016
Fibrinogen and CRP biomarkers in patients with exacerbation of COPD group C and D
Source: International Congress 2014 – Systemic biomarkers for airway diseases
Year: 2014
Analysis of serum prohepcidin and hepcidin levels in COPD patients by stages and by patient cathegory
Source: Annual Congress 2013 –COPD treatment
Year: 2013
Conduct of a biomarker study in bronchiectasis patients: Correlation of neutrophil elastase activity and inflammatory load in induced sputum
Source: International Congress 2014 – Systemic and airway biomarkers
Year: 2014
Expression of HLA-DR in circulating polymorphonuclear neutrophils of COPD patients
Source: Annual Congress 2013 –COPD: new markers of diseases
Year: 2013
PP102 – A serum biomarker reflecting human neutrophil elastase degraded calprotectin is elevated in COPD and IPF
Source: ERS Lung Science Conference 2021
Year: 2021
Concentration of C-reactive protein (CRP) in elderly asthmatics
Source: International Congress 2015 – Clincal aspects of asthma: monitoring and mechanisms
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept